ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102

Also written as “GI-102”, “GI-102 in combination with GIB-7” and “GI-102 subcutaneous (SC)”.

Its studies are mostly in Prostatic Neoplasms · Neoplasm Metastasis, led by GI Innovation.

Drug pageBispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Mar 28, 20233 company-led studies, 3 open or runningNext primary completion: Mar 31, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GI Innovation33 open or runningphase 2since Mar 28, 2023Mar 28, 2023Mar 31, 2029phase 2 · NCT07871435

Also a collaborator on its studies: Johnson & Johnson, GILongevity and Merck.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 28, 2023First study: phase 2 study in Neoplasm MetastasisFirst studyNCT05824975 · 358 planned · United States, Korea, Republic of
  2. Dec 2, 2025Phase 2 study in Cancer SurvivorsNCT07363057 · 15 planned · Australia
  3. Oct 1, 2026Phase 2 study in Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT07871435 · 107 planned · United States, South Korea

Ahead

  1. Mar 31, 2029Primary completion: phase 2 study in Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT07871435

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07871435Metastatic Castration-resistant Prostate Cancer (mCRPC) · United States, South Korea2RecruitingMar 31, 2029107
NCT07363057Cancer Survivors · Australia2RecruitingMay 202615
NCT05824975Neoplasm Metastasis · United States, Korea, Republic of2RecruitingNov 12, 2025358

How it is read

Names in the registry

  • “GI-102”, 3 entries
  • “GI-102 in combination with GIB-7”, 1 entry
  • “GI-102 subcutaneous (SC)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.